Lindbrook Capital LLC Sells 117 Shares of Becton, Dickinson and Company (NYSE:BDX)

Lindbrook Capital LLC cut its holdings in Becton, Dickinson and Company (NYSE:BDX) by 11.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 918 shares of the medical instruments supplier’s stock after selling 117 shares during the quarter. Lindbrook Capital LLC’s holdings in Becton, Dickinson and Company were worth $224,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. OFI Invest Asset Management purchased a new position in shares of Becton, Dickinson and Company during the third quarter valued at approximately $25,000. Fortitude Family Office LLC purchased a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth about $35,000. Venturi Wealth Management LLC lifted its position in shares of Becton, Dickinson and Company by 552.0% in the 4th quarter. Venturi Wealth Management LLC now owns 163 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 138 shares during the period. Arlington Trust Co LLC bought a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at about $41,000. Finally, Headlands Technologies LLC purchased a new position in shares of Becton, Dickinson and Company during the third quarter valued at about $55,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.1 %

BDX stock opened at $233.88 on Tuesday. The company has a quick ratio of 0.64, a current ratio of 1.08 and a debt-to-equity ratio of 0.56. The business has a 50 day moving average of $239.81 and a 200 day moving average of $241.99. Becton, Dickinson and Company has a twelve month low of $229.40 and a twelve month high of $287.32. The firm has a market cap of $67.57 billion, a PE ratio of 55.42, a price-to-earnings-growth ratio of 1.93 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.39 by $0.29. The firm had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.73 billion. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. Becton, Dickinson and Company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.98 EPS. On average, research analysts forecast that Becton, Dickinson and Company will post 12.94 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Thomas J. Spoerel sold 282 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the sale, the senior vice president now owns 2,276 shares in the company, valued at $542,348.04. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on BDX. Raymond James lifted their price objective on Becton, Dickinson and Company from $269.00 to $275.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Barclays upped their price target on Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $280.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.